Amit Rakhit,

Amit Rakhit is an experienced pharmaceutical and biotech executive and has led teams in developing medicines to transform medical practice across multiple therapeutic areas, including oncology, neurology, rare diseases, and cardiovascular conditions. He is particularly interested in building innovative bridges between the biotech industry, health technology, and the patient community to better meet the needs of patients and their caregivers. He is currently the Chief Medical Officer at BlueRock Therapeutics.

His previous roles have been in various C-suite positions, helping companies build and grow from the start-up phase, IPO, and operating entities. He was most recently CEO at Flare Therapeutics and previously at Sporos Bioventures. Before this role, Amit was President and Chief Medical Officer at Ovid Therapeutics, where he joined in the start-up phase and worked with the team through the IPO and subsequent pipeline development.

Between 2011-2016, he had senior-level roles at Biogen, including Head of Worldwide Medical, where he led a team of approximately 800 professionals in medical activities for marketed and pipeline compounds in the disease areas of multiple sclerosis, neurodegenerative diseases, dementia, and hemophilia. He also led the global development programs for therapies in orphan and rare disorders, such as dexpramipexole for ALS and Spinraza (nusinersen) for spinal muscular atrophy.

Before Biogen, he was with Bristol-Myers Squibb, where he led an international medical team of 300+ professionals across 27 countries with a cross-therapeutic area focus that included cardiovascular, metabolics, oncology, HIV, virology, immunology, and neuroscience products.

His education includes Harvard fellowship training in Pediatric Cardiology at Boston Children’s Hospital, MD from Tufts University, a BA from the University of California, Berkeley, and dual MBAs from Columbia Business School and London Business School.